Aptevo Therapeutics Inc. Research and Development Expense
Aptevo Therapeutics Inc. (APVO) reported Research and Development Expense of $3.70 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-14
- Aptevo Therapeutics Inc. research and development expense for the quarter ending 2026-06-30 was $3.70M, a 11.06% increase year-over-year.
- Aptevo Therapeutics Inc. research and development expense for the quarter ending 2026-03-31 was $3.92M, a 8.01% increase year-over-year.
- Aptevo Therapeutics Inc. research and development expense for the quarter ending 2025-12-31 was $3.54M, a 8.89% decline year-over-year.
- Aptevo Therapeutics Inc. research and development expense for the quarter ending 2025-09-30 was $4.04M, a 30.33% increase year-over-year.
- Aptevo Therapeutics Inc. research and development expense for fiscal 2025 was $14.54M, a 1.13% increase from fiscal 2024.
- Aptevo Therapeutics Inc. research and development expense for fiscal 2024 was $14.38M, a 15.95% decline from fiscal 2023.
- Aptevo Therapeutics Inc. research and development expense for fiscal 2023 was $17.11M, a 4.33% decline from fiscal 2022.
- Aptevo Therapeutics Inc. research and development expense for fiscal 2022 was $17.88M, a 5.85% decline from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $3.70M 10-Q · filed 2026-08-14 | $7.62M 10-Q · filed 2026-08-14 | $11.15M derived: sum of 3 quarters · filed 2026-08-14 | $15.20M derived: sum of 4 quarters · filed 2026-08-14 | ||||
| 2026-03-31 | $3.92M 10-Q · filed 2026-05-13 | $7.46M derived: sum of 2 quarters · filed 2026-05-13 | $11.50M derived: sum of 3 quarters · filed 2026-05-13 | $14.83M derived: sum of 4 quarters · filed 2026-08-14 | ||||
| 2025-12-31 | $3.54M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $7.58M derived: sum of 2 quarters · filed 2026-03-26 | $10.91M derived: sum of 3 quarters · filed 2026-08-14 | $14.54M 10-K · filed 2026-03-26 | ||||
| 2025-09-30 | $4.04M 10-Q · filed 2025-11-06 | $7.37M derived: sum of 2 quarters · filed 2026-08-14 | $11.01M 10-Q · filed 2025-11-06 | $14.88M derived: sum of 4 quarters · filed 2026-08-14 | ||||
| 2025-06-30 | $3.33M 10-Q · filed 2026-08-14 | $6.96M 10-Q · filed 2026-08-14 | $10.84M derived: sum of 3 quarters · filed 2026-08-14 | $13.94M derived: sum of 4 quarters · filed 2026-08-14 | ||||
| 2025-03-31 | $3.63M 10-Q · filed 2026-05-13 | $7.51M derived: sum of 2 quarters · filed 2026-05-13 | $10.62M derived: sum of 3 quarters · filed 2026-05-13 | $14.26M derived: sum of 4 quarters · filed 2026-05-13 | ||||
| 2024-12-31 | $3.88M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $6.98M derived: sum of 2 quarters · filed 2026-03-26 | $10.63M derived: sum of 3 quarters · filed 2026-03-26 | $14.38M 10-K · filed 2026-03-26 | ||||
| 2024-09-30 | $3.10M 10-Q · filed 2025-11-06 | $6.75M derived: sum of 2 quarters · filed 2025-11-06 | $10.50M 10-Q · filed 2025-11-06 | $14.09M derived: sum of 4 quarters · filed 2025-11-06 | ||||
| 2024-06-30 | $3.64M 10-Q · filed 2025-08-11 | $7.39M 10-Q · filed 2025-08-11 | $10.99M derived: sum of 3 quarters · filed 2025-08-11 | $14.87M derived: sum of 4 quarters · filed 2025-08-11 | ||||
| 2024-03-31 | $3.75M 10-Q · filed 2025-05-15 | $7.34M derived: sum of 2 quarters · filed 2025-05-15 | $11.23M derived: sum of 3 quarters · filed 2025-05-15 | $16.69M derived: sum of 4 quarters · filed 2025-05-15 | ||||
| 2023-12-31 | $3.59M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-14 | $7.48M derived: sum of 2 quarters · filed 2025-02-14 | $12.94M derived: sum of 3 quarters · filed 2025-02-14 | $17.11M 10-K · filed 2025-02-14 | ||||
| 2023-09-30 | $3.89M 10-Q · filed 2024-11-07 | $9.35M derived: sum of 2 quarters · filed 2024-11-07 | $13.52M 10-Q · filed 2024-11-07 | $18.19M derived: sum of 4 quarters · filed 2024-11-07 | ||||
| 2023-06-30 | $5.46M 10-Q · filed 2024-08-08 | $9.63M 10-Q · filed 2024-08-08 | $14.30M derived: sum of 3 quarters · filed 2024-08-08 | $18.78M derived: sum of 4 quarters · filed 2024-08-08 | ||||
| 2023-03-31 | $4.17M 10-Q · filed 2024-05-08 | $8.84M derived: sum of 2 quarters · filed 2024-05-08 | $13.32M derived: sum of 3 quarters · filed 2024-05-08 | $17.18M derived: sum of 4 quarters · filed 2024-05-08 | ||||
| 2022-12-31 | $4.67M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | $9.15M derived: sum of 2 quarters · filed 2024-03-05 | $13.02M derived: sum of 3 quarters · filed 2024-03-05 | $17.88M 10-K · filed 2024-03-05 | ||||
| 2022-09-30 | $4.48M 10-Q · filed 2023-11-14 | $8.34M derived: sum of 2 quarters · filed 2023-11-14 | $13.21M 10-Q · filed 2023-11-14 | $17.75M derived: sum of 4 quarters · filed 2023-11-14 | ||||
| 2022-06-30 | $3.87M 10-Q · filed 2023-08-10 | $8.73M 10-Q · filed 2023-08-10 | $13.27M derived: sum of 3 quarters · filed 2023-08-10 | $17.64M derived: sum of 4 quarters · filed 2023-08-10 | ||||
| 2022-03-31 | $4.87M 10-Q · filed 2023-05-11 | $9.41M derived: sum of 2 quarters · filed 2023-05-11 | $13.78M derived: sum of 3 quarters · filed 2023-05-11 | $18.50M derived: sum of 4 quarters · filed 2023-05-11 | ||||
| 2021-12-31 | $4.54M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $8.91M derived: sum of 2 quarters · filed 2023-03-30 | $13.63M derived: sum of 3 quarters · filed 2023-03-30 | $18.99M 10-K · filed 2023-03-30 | ||||
| 2021-09-30 | $4.37M 10-Q · filed 2022-11-10 | $9.09M derived: sum of 2 quarters · filed 2022-11-10 | $14.45M 10-Q · filed 2022-11-10 | $19.36M derived: sum of 4 quarters · filed 2022-11-10 | ||||
| 2021-06-30 | $4.72M 10-Q · filed 2022-08-11 | $10.08M 10-Q · filed 2022-08-11 | $15.00M derived: sum of 3 quarters · filed 2022-08-11 | $19.49M derived: sum of 4 quarters · filed 2022-08-11 | ||||
| 2021-03-31 | $5.36M 10-Q · filed 2022-05-12 | $10.27M derived: sum of 2 quarters · filed 2022-05-12 | $14.77M derived: sum of 3 quarters · filed 2022-05-12 | $19.21M derived: sum of 4 quarters · filed 2022-05-12 | ||||
| 2020-12-31 | $4.91M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-24 | $9.41M derived: sum of 2 quarters · filed 2022-03-24 | $13.85M derived: sum of 3 quarters · filed 2022-03-24 | $17.85M 10-K · filed 2022-03-24 | ||||
| 2020-09-30 | $4.49M 10-Q · filed 2021-11-12 | $8.93M derived: sum of 2 quarters · filed 2021-11-12 | $12.94M 10-Q · filed 2021-11-12 | $17.35M derived: sum of 4 quarters · filed 2021-11-12 | ||||
| 2020-06-30 | $4.44M 10-Q · filed 2021-08-12 | $8.45M 10-Q · filed 2021-08-12 | $12.85M derived: sum of 3 quarters · filed 2021-08-12 | $20.45M derived: sum of 4 quarters · filed 2021-08-12 | ||||
| 2020-03-31 | $4.01M 10-Q · filed 2021-05-11 | $8.41M derived: sum of 2 quarters · filed 2021-05-11 | $16.01M derived: sum of 3 quarters · filed 2021-05-11 | $22.14M derived: sum of 4 quarters · filed 2021-05-11 | ||||
| 2019-12-31 | $4.41M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | $12.00M derived: sum of 2 quarters · filed 2021-03-31 | $18.13M derived: sum of 3 quarters · filed 2021-03-31 | $24.76M 10-K · filed 2021-03-31 | $29.76M 10-K · filed 2020-03-25 | |||
| 2019-09-30 | $7.60M 10-Q · filed 2020-11-10 | $9.13M 10-Q · filed 2019-11-07 | $13.72M derived: sum of 2 quarters · filed 2020-11-10 | $20.36M 10-Q · filed 2020-11-10 | $24.14M 10-Q · filed 2019-11-07 | $29.25M derived: sum of 4 quarters · filed 2020-11-10 | ||
| 2019-06-30 | $6.13M 10-Q · filed 2020-08-14 | $7.73M 10-Q · filed 2019-08-09 | $12.76M 10-Q · filed 2020-08-14 | $15.02M 10-Q · filed 2019-08-09 | $21.66M derived: sum of 3 quarters · filed 2020-08-14 | $30.23M derived: sum of 4 quarters · filed 2020-08-14 | ||
| 2019-03-31 | $6.63M 10-Q · filed 2020-05-13 | $7.29M 10-Q · filed 2019-05-09 | $15.53M derived: sum of 2 quarters · filed 2020-05-13 | $24.11M derived: sum of 3 quarters · filed 2020-05-13 | $33.82M derived: sum of 4 quarters · filed 2020-05-13 | |||
| 2018-12-31 | $8.90M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-25 | $17.47M derived: sum of 2 quarters · filed 2020-03-25 | $27.19M derived: sum of 3 quarters · filed 2020-03-25 | $35.38M 10-K · filed 2020-03-25 | ||||
| 2018-09-30 | $8.57M 10-Q · filed 2019-11-07 | $18.29M derived: sum of 2 quarters · filed 2019-11-07 | $26.49M 10-Q · filed 2019-11-07 | $35.67M derived: sum of 4 quarters · filed 2019-11-07 | ||||
| 2018-06-30 | $9.71M 10-Q · filed 2019-08-09 | $17.91M 10-Q · filed 2019-08-09 | $27.10M derived: sum of 3 quarters · filed 2019-08-09 | $34.27M derived: sum of 4 quarters · filed 2019-08-09 | ||||
| 2018-03-31 | $8.20M 10-Q · filed 2019-05-09 | $17.39M derived: sum of 2 quarters · filed 2019-05-09 | $24.56M derived: sum of 3 quarters · filed 2019-05-09 | $31.35M derived: sum of 4 quarters · filed 2019-05-09 | ||||
| 2017-12-31 | $9.19M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18 | $16.36M derived: sum of 2 quarters · filed 2019-03-18 | $23.15M derived: sum of 3 quarters · filed 2019-03-18 | $29.02M 10-K · filed 2019-03-18 | ||||
| 2017-09-30 | $7.17M 10-Q · filed 2018-11-14 | $13.96M derived: sum of 2 quarters · filed 2018-11-14 | $19.84M 10-Q · filed 2018-11-14 | $26.20M derived: sum of 4 quarters · filed 2018-11-14 | ||||
| 2017-06-30 | $6.79M 10-Q · filed 2018-08-09 | $6.79M 10-Q · filed 2017-08-10 | $12.66M 10-Q · filed 2018-08-09 | $12.70M 10-Q · filed 2017-08-10 | $19.02M derived: sum of 3 quarters · filed 2018-08-09 | $26.10M derived: sum of 4 quarters · filed 2018-08-09 | ||
| 2017-03-31 | $5.87M 10-Q · filed 2018-05-10 | $5.91M 10-Q · filed 2017-05-12 | $12.23M derived: sum of 2 quarters · filed 2018-05-10 | $19.31M derived: sum of 3 quarters · filed 2018-05-10 | $26.95M derived: sum of 4 quarters · filed 2018-05-10 | |||
| 2016-12-31 | $6.36M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-13 | $13.44M derived: sum of 2 quarters · filed 2018-03-13 | $21.07M derived: sum of 3 quarters · filed 2018-03-13 | $29.12M 10-K · filed 2018-03-13 | $29.52M 10-K · filed 2017-03-31 | |||
| 2016-09-30 | $7.08M 10-Q · filed 2017-11-13 | $7.11M 10-Q · filed 2016-11-14 | $14.71M derived: sum of 2 quarters · filed 2017-11-13 | $22.76M 10-Q · filed 2017-11-13 | $22.85M 10-Q · filed 2016-11-14 | $30.22M derived: sum of 4 quarters · filed 2017-11-13 | ||
| 2016-06-30 | $7.64M 10-Q · filed 2017-08-10 | $15.74M 10-Q · filed 2017-08-10 | $23.14M derived: sum of 3 quarters · filed 2017-08-10 | $30.86M derived: sum of 4 quarters · filed 2017-08-10 | ||||
| 2016-03-31 | $8.10M 10-Q · filed 2017-05-12 | $15.51M derived: sum of 2 quarters · filed 2017-05-12 | $23.22M derived: sum of 3 quarters · filed 2017-05-12 | $33.73M derived: sum of 4 quarters · filed 2017-05-12 | ||||
| 2015-12-31 | $7.41M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-31 | $15.12M derived: sum of 2 quarters · filed 2017-03-31 | $25.63M derived: sum of 3 quarters · filed 2017-03-31 | $34.73M 10-K · filed 2017-03-31 | ||||
| 2015-09-30 | $7.71M 10-Q · filed 2016-11-14 | $18.22M derived: sum of 2 quarters · filed 2016-11-14 | $27.32M 10-Q · filed 2016-11-14 | |||||
| 2015-06-30 | $10.51M 10-Q/A · filed 2016-09-22 | $19.61M 10-Q/A · filed 2016-09-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B |